Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Total Debt (2016 - 2025)

BioCorRx (BICX) has disclosed Total Debt for 11 consecutive years, with $69803.0 as the latest value for Q3 2025.

  • Quarterly Total Debt fell 94.25% to $69803.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $69803.0 through Sep 2025, down 94.25% year-over-year, with the annual reading at $71029.0 for FY2024, 92.89% down from the prior year.
  • Total Debt hit $69803.0 in Q3 2025 for BioCorRx, down from $71029.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $3.1 million in Q2 2022 to a low of $69803.0 in Q3 2025.
  • Historically, Total Debt has averaged $1.3 million across 5 years, with a median of $999088.0 in 2023.
  • Biggest five-year swings in Total Debt: plummeted 95.57% in 2021 and later surged 1252.86% in 2023.
  • Year by year, Total Debt stood at $105880.0 in 2021, then tumbled by 30.25% to $73850.0 in 2022, then soared by 1252.86% to $999088.0 in 2023, then plummeted by 92.89% to $71029.0 in 2024, then decreased by 1.73% to $69803.0 in 2025.
  • Business Quant data shows Total Debt for BICX at $69803.0 in Q3 2025, $71029.0 in Q4 2024, and $1.2 million in Q3 2024.